(245 days)
Not Found
No
The document explicitly states "CardioDay® does not perform any diagnosis of data by itself but only displays ECG morphologies and associated, calculated graphs". It also mentions "Mentions AI, DNN, or ML: Not Found".
No
Explanation: This device is a software for analyzing ECG data and is intended to assist physicians in interpretation, not to provide therapy or direct treatment.
Yes
The device aids in the "Evaluation of symptoms that may be caused by cardiac arrhythmia and/or conduction disturbances" and "Detection of ECG events that alter prognosis in certain forms of heart disease," both of which are diagnostic activities. While it states it does not perform diagnosis by itself, it assists the physician in interpreting data for diagnostic purposes.
Yes
The device description explicitly states "CardioDay® is a software package". While it processes data from an ECG recording device (which is hardware), the device being cleared by this 510(k) is the software itself, which performs the analysis, review, and reporting functions. The performance studies listed focus on software development lifecycle, risk management, usability, security, and interface testing, further supporting its classification as a software-only device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices intended for use in vitro for the examination of specimens, including blood, tissue, and urine, derived from the human body, to provide information for diagnostic, monitoring, or compatibility purposes.
- CardioDay V2.5 Function: The CardioDay V2.5 software analyzes ECG data, which is a recording of the electrical activity of the heart. This data is acquired directly from the patient's body using electrodes, not from a specimen taken from the body.
- Intended Use: The intended use clearly states it's for the acquisition, analysis, edit, review, report, and storage of ambulatory and multi-parameter ECG data. This is focused on analyzing physiological signals, not biological specimens.
- Device Description: The description reinforces that it analyzes "long-term continuous electrocardiographic (ECG) recording," further confirming it works with electrical signals from the body.
Therefore, because the device analyzes physiological data (ECG) acquired directly from the patient rather than biological specimens, it falls outside the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The CardioDay V2.5 Holter Analysis Software is designed for the acquisition, analysis, edit, review, report, and storage of ambulatory and multi-parameter ECG data.
Results of the automated analysis are intended to assist the physician in the interpretation of the recorded data. This information is not intended to serve as a substitute for the physician overread of the recorded ECG data.
The CardioDay V2.5 system is intended to be used by trained operators under the direct supervision of a licensed healthcare practitioner in a hospital or clinic environment.
Patient population includes both adult and pediatric human patients.
CardioDay V2.5 provides the user arrhythmia study and Holter analysis capabilities.
Data acquired may be used for the following indications:
- · Evaluation of symptoms that may be caused by cardiac arrhythmia and/or conduction disturbances,
- · Evaluation of symptoms that may be due to myocardial ischemia,
- · Detection of ECG events that alter prognosis in certain forms of heart disease.
- · Detection and analysis of pacemaker function and failure,
- · Determination of cardiac response to lifestyle,
- · Evaluation of therapeutic interventions,
- · Investigations in epidemiology and clinical trials.
Prescription Device Statement: United States federal law restricts CardioDay to sale by or on the order of a physician.
Product codes
DQK
Device Description
CardioDay® is a software package that allows a trained physician or health care professional knowledgeable in Holter interpretation, after having performed a long-term continuous electrocardiographic (ECG) recording, to download and analyze the data, review it and produce printed reports. CardioDay® does not perform any diagnosis of data by itself but only displays ECG morphologies and associated, calculated graphs such as heart rate trends, RR variability, and other statistical values in graphical form. The physician will be able to review, edit, and print the data collected.
The following Interfacing Devices (not part of this 510(k)) are supported by CardioDay V2.5:
- CardioMem CM 3000 (identical to CardioDay V2.4) ●
- . CardioMem CM 3000Z (identical to CardioDay V2.4)
- CardioMem CM 3000-12BT (identical to CardioDay V2.4) ●
- CardioMem CM 4000(B) (identical to CardioDay V2.4) ●
- SEER 12 (identical to CardioDay V2.4) ●
- SEER Light (new in CardioDay V2.5)
- SEER Light Extend (new in CardioDay V2.5) ●
- SEER 1000 (24h, 48h and 7-day models) (identical to CardioDay V2.4) ●
- . Care Scape Gateway (new in CardioDay V2.5)
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
adult and pediatric human patients.
Intended User / Care Setting
trained operators under the direct supervision of a licensed healthcare practitioner in a hospital or clinic environment.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical testing that has been conducted includes:
- a. ECG performance testing according to AAMI / ANSI / IEC 60601-2-47:
- b. Software development life cycle according to IEC 62304;
- c. Risk management process according to AAMI / ANSI / ISO 14971 and IEC /TR80002-1;
- d. Usability engineering process according to AAMI / ANSI / IEC 62366-1 and IEC 60601-1-6;
- e. Security tests to fulfill FDA Guidance for cybersecurity;
- f. Interface tests to fulfill FDA Guidance for interoperability.
None of the testing demonstrated that CardioDay® V2.5 brought up any issues of safety or effectiveness.
7 Discussion of Clinical Tests Performed
No clinical testing was performed in order to support safety or effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1425 Programmable diagnostic computer.
(a)
Identification. A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized image of an eagle with three heads, representing the department's commitment to health, human services, and science. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle image.
March 24, 2017
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
GETEMED Medizin- und Informationstechnik AG Bert Schadow Regulatory Affairs Manager Oderstrasse 77 Teltow, 14513 DE
Re: K162023
Trade/Device Name: CardioDay V2.5 Regulation Number: 21 CFR 870.1425 Regulation Name: Programmable Diagnostic Computer Regulatory Class: Class II Product Code: DQK Dated: July 19, 2016 Received: July 22, 2016
Dear Bert Schadow:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely.
Mude Jellman
for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
K162023
Device Name CardioDay V2.5
Indications for Use (Describe)
The CardioDay V2.5 Holter Analysis Software is designed for the acquisition, analysis, edit, review, report, and storage of ambulatory and multi-parameter ECG data.
Results of the automated analysis are intended to assist the physician in the interpretation of the recorded data. This information is not intended to serve as a substitute for the physician overread of the recorded ECG data.
The CardioDay V2.5 system is intended to be used by trained operators under the direct supervision of a licensed healthcare practitioner in a hospital or clinic environment.
Patient population includes both adult and pediatric human patients.
CardioDay V2.5 provides the user arrhythmia study and Holter analysis capabilities.
Data acquired may be used for the following indications:
- · Evaluation of symptoms that may be caused by cardiac arrhythmia and/or conduction disturbances,
- · Evaluation of symptoms that may be due to myocardial ischemia,
- · Detection of ECG events that alter prognosis in certain forms of heart disease.
- · Detection and analysis of pacemaker function and failure,
- · Determination of cardiac response to lifestyle,
- · Evaluation of therapeutic interventions,
- · Investigations in epidemiology and clinical trials.
Prescription Device Statement: United States federal law restricts CardioDay to sale by or on the order of a physician.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
| DHF - Technical Documentation | @getemed |
|---|---|
| CardioDay V2.5 | 1450-TD-0033-00 |
| 510(K) SUMMARY - Assigned 510(k) number: K162023 | Rev 04 |
1 510(K) SUMMARY
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.
The assigned 510(k) number is: K162023
| Submitted By: | GETEMED Medizin- und Informationstechnik AG
Oderstrasse 77, 14513 Teltow, Germany
Tel: + 49 - 3328 3942 0 |
|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact: | Dr. Bert Schadow
Regulatory Affairs Manager
GETEMED Medizin- und Informationstechnik AG
Oderstrasse 77, 14513 Teltow, GERMANY
Tel: + 49 – 3328 3942 70
Fax: + 49 - 3328 3942 99 |
| Manufacturing Facility: | GETEMED Medizin- und Informationstechnik AG
Oderstrasse 77, 14513 Teltow, GERMANY |
| Date of Preparation: | March 22, 2017 |
| Name of the Device: | CardioDay® V2.5 |
| Common or Usual Name: | Holter evaluation software |
| Classification Name: | Computer, Diagnostic, Programmable |
| Product Classification: | 21 CFR 870.1425, Class II |
| Product Code: | DQK |
Predicate Device Information:
| Device | Manufacturer | 510(k) Number |
|---|---|---|
| Primary Predicate Device: | ||
| CardioDay® version 2.4 | GETEMED Medizin- und | |
| Informationstechnik AG | K130516 | |
| Secondary Predicate Device: | ||
| MARS Holter Analysis | ||
| Workstation | GE Medical Systems | |
| Information Technologies | K132437 |
2 Reason for Submission
Premarket notification for CardioDay® V2.5, a New Device, seeking authority to market the device under Section 510(k) as a device that is substantially equivalent to the evaluation software CardioDay version 2.4 (K130516, GETEMED Medizin- und Informationstechnik AG) and MARS (K132437, GE Medical Systems Information Technologies).
4
| DHF - Technical Documentation | @getemed |
|---|---|
| CardioDay V2.5 | 1450-TD-0033-00 |
| 510(K) SUMMARY - Assigned 510(k) number: K162023 | Rev 04 |
3 Device Description
CardioDay® is a software package that allows a trained physician or health care professional knowledgeable in Holter interpretation, after having performed a long-term continuous electrocardiographic (ECG) recording, to download and analyze the data, review it and produce printed reports. CardioDay® does not perform any diagnosis of data by itself but only displays ECG morphologies and associated, calculated graphs such as heart rate trends, RR variability, and other statistical values in graphical form. The physician will be able to review, edit, and print the data collected.
The following Interfacing Devices (not part of this 510(k)) are supported by CardioDay V2.5:
- CardioMem CM 3000 (identical to CardioDay V2.4) ●
- . CardioMem CM 3000Z (identical to CardioDay V2.4)
- CardioMem CM 3000-12BT (identical to CardioDay V2.4) ●
- CardioMem CM 4000(B) (identical to CardioDay V2.4) ●
- SEER 12 (identical to CardioDay V2.4) ●
- SEER Light (new in CardioDay V2.5)
- SEER Light Extend (new in CardioDay V2.5) ●
- SEER 1000 (24h, 48h and 7-day models) (identical to CardioDay V2.4) ●
- . Care Scape Gateway (new in CardioDay V2.5)
ব Intended Use
The CardioDav V2.5 Holter Analysis Software is designed for the acquisition, analysis, edit, review, report, and storage of ambulatory and multi-parameter ECG data.
Results of the automated analysis are intended to assist the physician in the interpretation of the recorded data. This information is not intended to serve as a substitute for the physician overread of the recorded ECG data.
The CardioDay V2.5 system is intended to be used by trained operators under the direct supervision of a licensed healthcare practitioner in a hospital or clinic environment. Patient population includes both adult and pediatric human patients.
CardioDay V2.5 provides the user arrhythmia study and Holter analysis capabilities. Data acquired may be used for the following indications:
• Evaluation of symptoms that may be caused by cardiac arrhythmia and/or conduction disturbances,
- · Evaluation of symptoms that may be due to myocardial ischemia.
- · Detection of ECG events that alter prognosis in certain forms of heart disease.
- · Detection and analysis of pacemaker function and failure,
- · Determination of cardiac response to lifestyle,
- · Evaluation of therapeutic interventions,
- · Investigations in epidemiology and clinical trials.
Prescription Device Statement:
United States federal law restricts CardioDay® to sale by or on the order of a physician.
5
| DHF – Technical Documentation | getemed | |
|---|---|---|
| CardioDay V2.5 | 1450-TD-0033-00 | |
| 510(K) SUMMARY - Assigned 510(k) number: K162023 | Rev 04 |
5 Comparison to Predicate Devices
The primary predicate device is CardioDay version 2.4 (K130516). There have been no changes implemented in the modifications to CardioDay® V2.5 that impact the fundamental technology. The indications for use from CardioDay® version 2.4 (K130516) was adapted to the indications for use from MARS (K132437) in order to clarify the indications without affecting the substance or meaning of the indications.
As all indications for use cover the same diagnostic scope, i.e. patients suffering from cardiac related illnesses or complaining of potentially having such illnesses, as well as patients wearing a pacemaker, the Holter evalution software CardioDay® V2.5 can be regarded as substantially equivalent to CardioDay® version 2.4 (K130516) from GETEMED Medizin- und Informationstechnik AG and MARS Holter Analysis Workstation (K132437) from GE Medical Systems Information Technologies.
The following incremental changes were also made:
- Graphical user interface -> OEM Version for GE Healthcare;
- MUSE Import/Export Option (order management implemented);
- ECG Monitor Import Option (via Carescape Gateway from GE Healthcare) and support of SEER Light Holter recorders;
- Software Licensing Concept with Single Sign-On;
- Bluetooth Hook-Up Process for SEER 1000 Holter recorders;
- Error Logging implemented
A detailed discussion of similarities and differences is provided as a table of comparison in this 510(k) submission.
6 Discussion of Non-Clinical Tests Performed for Determination of Substantial Equivalence are as follows
Non-clinical testing that has been conducted includes:
- a. ECG performance testing according to AAMI / ANSI / IEC 60601-2-47:
- b. Software development life cycle according to IEC 62304;
- c. Risk management process according to AAMI / ANSI / ISO 14971 and IEC /TR80002-1;
- d. Usability engineering process according to AAMI / ANSI / IEC 62366-1 and IEC 60601-1-6;
- e. Security tests to fulfill FDA Guidance for cybersecurity;
- f. Interface tests to fulfill FDA Guidance for interoperability.
None of the testing demonstrated that CardioDay® V2.5 brought up any issues of safety or effectiveness.
7 Discussion of Clinical Tests Performed
No clinical testing was performed in order to support safety or effectiveness.
8 Conclusion
CardioDay® V2.5 is identical to its predicate device in intended use / indications for use and operating principle. Verification and validation of CardioDay V2.5 demonstrated that the incremental changes do not raise any new questions of safety and effectiveness to the subject device and the subject device is substantially equivalent to the predicate devices.